



DMSG Scientific Symposium

“BCMA targeted therapy – uses and perspectives”

Thursday, 3 November 2022

First Hotel Grand, Jernbanegade 18, 5000 Odense C, Denmark

Program (updated on 2 October 2022)

- 13.00-14.00 Arrival and lunch
- 14.00-14.10 Welcome. Emil Hermansen, chair DMSG
- 14.10-14.50 *How do we treat MM patients in Germany.* Professor Hartmut Goldschmidt, Heidelberg, Germany.
- 14.50-15.30 *Improving the targets in multiple myeloma: Future CAR-T strategies.* Jakub Krejčík, MD, PhD. Odense University Hospital.
- 15.30-16.00 Coffee and posters
- 16.00-16.30 *Upcoming BCMA studies.* Fredrik Schjesvold, MD, PhD. Oslo Myeloma Center, Norway.
- 16.30-17.00 *Side effects of BCMA targeted therapies.* Sarah Farmer, MD, PhD. Vejle Hospital.
- 17.00-17.20 Panel discussion: *Optimal patient selection and sequencing of BCMA therapies?*
- 17.20-17.30 Break
- 17.30-18.00 *DMSG Young Investigator Award 2022.*
- Introduction and award: Emil Hermansen & company representative
 - Acceptance speech by awardee
- 18.00 *Adjourn*

Registration at myeloma.dk: <https://myeloma.hematology.dk/index.php/dmsg>

The symposium is sponsored by pharmaceutical companies and the International Myeloma Foundation

